Mr. Michael Frank reports

REVIVE THERAPEUTICS PROVIDES UPDATE EVALUATING BUCILLAMINE FOR NERVE AGENT EXPOSURE WITH DEFENCE RESEARCH AND DEVELOPMENT CANADA

Revive Therapeutics Ltd. has released an update on the company's project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada -- Suffield Research Centre, an agency of the Canadian Department of National Defence. The company and the DRDC have finalized the research protocol and expect the project to be completed by the end of the second quarter of 2024.

DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury. Recent studies have shown that anti-oxidant compounds such as n-acetylcysteine (NAC) could be beneficial in limiting seizure activity and improving the anti-convulsant efficacy of GABA-mediating drugs such as diazepam. Bucillamine is a significantly more effective anti-oxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anti-coagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anti-convulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional anti-oxidant effects on seizure activity and survival will also be assessed.

The results from this research, if promising, will determine further studies to facilitate Health Canada approval for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning and potentially begin initial studies for efficacy against mild traumatic brain injury caused by concussive or explosive forces. In addition, the company and the DRDC may determine developing novel formulations of Bucillamine and potentially support the development of the company's next-generation lyophilized formulation of Bucillamine (New Bucillamine) that was successfully completed at the University of Waterloo.

The New Bucillamine has the potential to unlock the therapeutic utility of Bucillamine for treating public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. Also, the company may explore the New Bucillamine as a potent anti-oxidant and anti-inflammatory, for rare inflammatory disorders such as ischemia-reperfusion injury (for example organ transplantation), which the Food and Drug Administration granted orphan drug designation for in 2022.

About Revive Therapeutics Ltd.

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as emergency use authorization, orphan drug, fast track and breakthrough therapy designations. Currently, the company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of psilocybin-based therapeutics through various programs.

We seek Safe Harbor.